Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes)

NCT00211224 is registered in ClinicalTrials.gov with King's College London as lead sponsor.

NCT NCT00211224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00211224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes)
Lead sponsor
King's College London
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2000
Completion date
November 30, 2004
Enrollment
800
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple system atrophy, progressive supranuclear palsy